ASCO Chicago to Spotlight Pancreatic Cancer, GSK Cure
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Engineered heart patches are reporting early but meaningful progress, according to scientists.
- GSK has a functional cure for hepatitis B for at least some of the patient population.
- Trump's claim about the U.S. having “most‑favored nation” status can be tested by new drug launches.
- ASCO will convene in Chicago, with pancreatic cancer expected to dominate the agenda.
Why it matters: Patients with hepatitis B—some of the patient population—who fit GSK’s new functional cure can finally achieve remission, while biotech firms eyeing ASCO’s pancreatic cancer focus stand to attract fresh capital, reshaping treatment pipelines.
